Sulfasalazine

CHEMBL421 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
398.4 g/mol
LogP
-0.7
Phase
4

Taken orally, this anti-inflammatory medication releases two active components in the colon — sulfapyridine and mesalazine — where they reduce the chronic inflammation driving conditions like Crohn's disease, ulcerative colitis, and rheumatoid arthritis. It is also being investigated for potential effects in certain cancers due to its ability to interfere with inflammatory signaling pathways.

Peso Molecular

398,4000 g/mol

LogP

-0,70

TPSA

150,00 Ų

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O

InChI

InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+

Molecular Formula

C18H14N4O5S

HBD / HBA

3 / 9

Ligações Rotacionáveis

6

Átomos Pesados

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

Taken orally, this anti-inflammatory medication releases two active components in the colon — sulfapyridine and mesalazine — where they reduce the chronic inflammation driving conditions like Crohn's disease, ulcerative colitis, and rheumatoid arthritis. It is also being investigated for potential effects in certain cancers due to its ability to interfere with inflammatory signaling pathways.

Yes, Sulfasalazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL421. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5339. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.